Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

NCT03062540 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
358
Enrollment
INDUSTRY
Sponsor class

Stopped Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.

Conditions

Interventions

Sponsor

Tonix Pharmaceuticals, Inc.

Collaborators